London · Delayed Price · Currency is GBP · Price in USD Centessa Pharmaceuticals Company Description
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
The company was formerly known as Centessa Pharmaceuticals Limited and changed its name to Centessa Pharmaceuticals plc in May, 2021.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, United Kingdom with an additional office in Boston, Massachusetts.
As of June 24, 2026, Centessa Pharmaceuticals plc operates as a subsidiary of Eli Lilly and Company.
| Country | United Kingdom |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 129 |
| CEO | Mario Accardi |
Contact Details
Address: 3rd Floor Altrincham, WA14 2DT United Kingdom | |
| Phone | 44 739 1789784 |
| Website | centessa.com |
Stock Details
| Ticker Symbol | 0ACX |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US1523091007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mario Alberto Accardi Ph.D. | Chief Executive Officer and Director |
| John J. Crowley CPA | Chief Financial Officer |
| Dr. Stephen J. Kanes M.D., Ph.D. | Head of Research & Development and Chief Medical Officer |
| Raphael Deferiere CPA | Senior Vice President and Chief Accounting Officer |
| Tia L. Bush | Chief Technology and Quality Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Iqbal J. Hussain L.L.B. | Chief Legal Officer, Chief Compliance Officer and Company Secretary |
| Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Charlene Stoudt | Senior Vice President of Clinical Development Operations |